A population-based cohort study emulating a target trial estimated the effect of glucagon-like peptide-1 receptor agonists ...

In patients with metabolic-associated steatotic liver disease or metabolic-associated steatohepatitis, resmetirom and ...

For adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide 1 ...

The molecule, developed in collaboration with Massachusetts-based Kailera Therapeutics, is headed for a new drug application ...

Glucagon-like peptide-1 (GLP-1) receptor agonists significantly enhance overall survival in patients with ovarian cancer, ...

DALLAS — Glucagon-like peptide-1 receptor agonists may reduce complications after total knee arthroplasty in patients with obesity but who are not diabetic, according to presented results.&ldquo ...

GLP-1 receptor agonists such as semaglutide and liraglutide promote significant weight loss and improved glycemic control, ...

SGLT2 inhibitors and GLP-1 receptor agonists lower cardiovascular risk in type 2 diabetes, but a recent review suggests that ...

GLP-1 Receptor Agonists in Patients With Obesity or Overweight. Obesity is defined as a body mass index (BMI) of 30 kg/m 2 or higher, whereas overweight is defined as a BMI of 25 kg/m 2 to 29.9 kg ...

Glucagon-like peptide-1 (GLP-1) receptor agonists -- your patients are on them, and perhaps you are too (or at least have thought about it). In 2023, more than 500 million people worldwide were ...

Canadian study reveals diabetic patients taking GLP-1 medications face twice the risk of eye problems, with longer exposure ...

About The Study: In patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP1-RA) treatment is not associated with increased risk of psychiatric ...